Fish Linked to Lower Dementia Risk, Once Again

Brain food

Brain food

Older adults in low- to middle-income countries seem to have a lower risk of dementia if they regularly eat fish, according to a new study in the American Journal of Clinical Nutrition.

This comes on the heels of another recent study questioning the anti-dementia protective effect of fish consumption.

Almost 15,000 people were surveyed in China, India, Cuba, Domincan Republic, Mexico, Peru, and Venezuela.  As fish intake increased – from never, to some days of the week, to most or all days of the week – dementia prevalence dropped by 19% for each increase of intake.  Data for the effect were less convincing for Indian populations. 

The prevalence of dementia also tended to rise with meat consumption.

Steve Parker, M.D.

Reference:  Albanese, Emiliano, et al.  Dietary fish and meat intake and dementia in Latin America, China, and India: a 10/66 Dementia Research Group population-based studyAmerican Journal of Clinical Nutrition, 90 (2009): 392-400.

Comments Off on Fish Linked to Lower Dementia Risk, Once Again

Filed under Fish, Health Benefits

Wine Safely Lowers Fasting Blood Sugar in Type 2 Diabetes

"Is the room spinning, or is it just me?"

"Is the room spinning, or is it just me?"

Wine consumption lowered fasting blood sugar levels by 15% in type 2 diabetics who had previously not been habitual drinkers, according to a 2007 study in Israel.

Background

Judicious alcohol consumption is linked to lower rates of cardiovascular disease (heart attack and stroke), longer lifespan, and lower risk of developing type 2 diabetes.  The beneficial health effects of alcohol seem to be more pronounced in people who already have type 2 diabetes. 

Israeli investigators wondered how initiation of an alcohol habit would effect fasting and after-meal blood glucose levels in type 2 diabetics.

Methodology

Researchers studied 109 type 2 diabetics (41-74 years old)  in Israel who previously had abstained from alcohol.  They were randomly assigned to drink either 150 ml (5 oz) of wine or nonalcoholic diet malt beer (as a control) during dinner daily for three months.  Wine choices were a dry red (Merlot) or white (Sauvignon Blanc).  Three out of four chose the Merlot.

Use of anti-diabetic medications was not reported.  People using more than two insulin injections daily or an insulin pump were excluded from participation.

Results

In the wine group, average fasting plasma glucose decreased by 21 mg/dl, from 139 to 118 mg/dl, a 15% drop.  [The authors calculated this as a 9.2% drop, but I stand by my calculation of 15%.]   Fasting glucose did not change in the control group. 

There was no difference between the groups in glucose levels measured two hours after dinner.

In the wine group, 5% reported low blood sugar, headaches, or weakness, and 8% reported increased sexual desire.  But these numbers were not statistically significant compared to the control group.

Patients with higher baseline hemoglobin A1c levels had greater reductions in fasting glucose.

The wine group reported an improved ability to fall asleep.

Three months after the end of the study, 61% of the wine group said they thought the alcohol was beneficial to them, and half of the group continued to drink in moderation.

Conclusions of the Investigators

Among patients with type 2 diabetes who had previously abstained from alcohol, initiation of moderate daily alcohol consumption reduced FPG [fasting plasma glucose] but not postprandial glucose.  Patients with higher A1C may benefit more from the favorable glycemic effect of alcohol.  Further intervention studies are needed to confirm the long-term effect of moderate alcohol intake.

My Comments

The investigators imply that the various types of alcohol – beer, wine, spirits (whiskey, vodka, gin, etc) – will have the same effect on fasting glucose levels.  The study at hand provides no evidence except for wine.   

Some type 2 diabetics have fasting glucose levels routinely as low as 80 mg/dl.  If they start drinking wine like this, dropping their fasting glucose to around 6o or less, they could end up with symptomatic hypoglycemia in the mornings, or even hypoglcymia while asleep.  Use caution.  I’ve read other studies indicating that hypoglycemia usually is not a problem with light to moderate alcohol consumption. 

The potential adverse health effects of alcohol are well-documented elsewhere, as are other reasons not to drink.

Diabetics who are diet-controlled, or on diabetic medications that don’t cause hypoglycmia by themselves, are unlikely to develop hypoglycmia with wine or other alcohol. 

Wine has significant potential to prolong life and reduce rates of cardiovascular disease in type 2 diabetes.  It will be years, if ever, before we have confirmatory studies.  Who’s going to pay for the research?  The California Winegrowers Association?

Steve Parker, M.D.    
View Steve Parker, M.D.'s profile on LinkedIn

Reference:  Shai, Iris, et al.  Glycemic effects of moderate alcohol intake among patients with type 2 diabetes: A multicenter, randomized, clinical intervention trialDiabetes Care, 30 (2007): 3,011-3,016. 

Disclaimer:  All matters regarding your health require supervision by a personal physician or other appropriate health professional familiar with your current health status.  Always consult your personal physician before making any dietary or exercise changes.

2 Comments

Filed under Alcohol

Atkins Diet Beats Low-Fat Diet Over Three Months in Overweight Diabetic Black Women

MPj04384250000[1]A recent study compared effects of a low-carb versus low-fat diet in overweight diabetics (mostly blacks).  After one year, the only major difference they found was  lower HDL cholesterol in the low-carb eaters.  The low-carb diet was more effective measured at three months into the study.  Study participants were overwhelmingly black women, so the findings may not apply to you.

Background

The authors note at the outset that:

Optimal weight loss strategies in patients with type 2 diabetes continue to be debated, and the best dietary strategy to achieve both weight loss and glycemic control . . . is unclear.

They also note that in short-term randomized studies, low-carb diets help improve glucose control in type 2 diabetics.

Methodology

Participants (105) were randomized to either:

  • a low-fat diet in the fashion of the Diabetes Prevention Program, with a fat gram goal of 25% of energy needs, or . . .
  • the Atkins diet, including the 2-week induction phase and gradually increasing carb grams weekly, etc.

The adult partipants were black (64%), Hispanic (16%), white (15%), or other.  Women were 80% of the group.  Average age 54.  Average weight 215 pounds (98 kg).  Average BMI 36.  Most of them were taking metformin, half were taking a sulfonylurea, 30% were on insulin.  Thiazolidinedione drugs were discontinued since they cause weight gain as a side effect.  Short-acting insulins were changed to glargine (Lantus) to help avoid hypoglycemia.  For the low-carb group initially, insulin dosages  were reduce by half and sulfonylureas were stopped (again, to minimize hypoglycemia).  For the low-fat group, insulin was reduced by 25% and sulfonylurea by 50%.  Metformin was not adjusted.  Subjects were instructed to keep daily food diaries.  Goal rate of weight loss was one pound per week.   

Results

The drop-out rate by the end of 12 months was the same in both groups – 20%.  The low-carbers lost weight faster (3.7 lb/month) in the first three months, but by month twelve each group had the same 3.4% reduction of weight (6.8 lb or 3 kg).  As measured at 3 months, low-carbers were down 11.4 lb (5.2 kg) and low-fat dieters were down 7 lb (3.2 kg).  Maximum weight loss was at 3 months, then they started gaining it back.  At 12 months, low-carb subjects using insulin were on 10 less units, while low-fat dieters were using 4 more units (not statistically significant).  Hemoglobin A1c measured at 3 months was down 0.64 in the low-carb group and down0.26 in the low-fat.  By 12 months, HgbA1c’s were back up to baseline levels for both groups.  Blood lipids were the same for both groups at 12 months except HDL was about 12% higher in the low-carb dieters.

At baseline, subjects derived 43% of calories from carbohydrates, 36% from fats, 23% from proteins.  At three months, the low-carb group ate 24% of calories as carbohydrates (estimated at 77 grams of carb daily) and 49% from fat.  The low-fat group at 3 months derived 53% of calories from carbohydrate (199 grams/day) and 25% from fat. Diet compliance deteriorated as time passed thereafter. 

Study Author Conclusions

After one year, the low-carb and low-fat groups had similar weight reductions.  The low-carb dieters raised their HDL cholesterol levels significantly [which may protect against heart disease].

My Comments

Lasting weight loss is difficult!  Down only 6.8 pounds for a year of  effort. 

These study participants needed to lose a lot more than 6.8 pounds.  They needed to lose 50.  Both groups were woefully noncompliant with diet recommendations by the end of the study year.  They were eating more carbs or other calories than they were assigned.  But their results weren’t much different than other groups studied for an entire year. 

How do we keep people fired up about maintaining their weight-loss efforts?  The solution to that problem will win someone a Nobel Prize.

The Atkins diet was superior – for weight loss and glycemic control – when measured at three months, when compliance by both groups was still probably fairly good.

Results of this study may apply only to black women.  There weren’t enough men and other ethnic groups to make meaningful comparisons.    

Steve Parker, M.D.        

Reference:  Davis, Nichola, et al.  Comparative study of the effects of a 1-year dietary intervention of a low-carbohydrate diet versus a low-fat diet on weight and glycemic control in type 2 diabetes.  Diabetes Care, 32 (2009): 1,147-1,152.

1 Comment

Filed under Carbohydrate, Weight Loss

Metformin May Reduce Pancreatic Cancer Risk in Diabetics

 

Reuters reported recently that people with type 2 diabetes using metformin had a 60% lower risk of developing pancreatic cancer compared with diabetics who never used metformin.  People taking insulin and drugs that stimulate insulin secretion,  such as sulfonylureas and glinides, also seem to be at higher risk of pancreas cancer. 

"OK, guys, are we ready to go get that cancer?"

"OK, guys, are we ready to go get that cancer?"

Lead researcher for the study, Donghui Li, is affiliated with the University of Texas M.D. Anderson Cancer Center.  My sense is that the research has not yet been published in a peer-reviewed professional journal. 

About one in every 75 people in the U.S. will develop pancreatic cancer, which is a particularly dangerous cancer.  That translates to 38,000 new cases yearly.  Both type 1 and type 2 diabetics are twice as likely as the general population to develop it.  The best chance for a cure is surgical removal of the malignancy.

Prevention is even better.

Steve Parker, M.D.

Reference:  Steenhuysen, Julie.  Drug cuts diabetics’ pancreatic cancer risk: study.  Reuters, August 3, 2009.

1 Comment

Filed under Diabetes Complications, Drugs for Diabetes

Potential Adverse Effects of Alcohol

In a recent blog post, I discussed the potential benefits of alcohol consumption on longevity, coronary artery disease, and dementia.

Not so fast there, buddy!

Not so fast there, buddy!

I have no intention of overselling the benefits of alcohol.  If you are considering habitual alcohol as a food, be aware that the health benefits are still somewhat debatable.  Consumption of three or more alcoholic drinks per day is clearly associated with a higher risk of breast cancer in women.  Even one or two drinks daily may slightly increase the risk.  Folic acid supplementation might mitigate the risk.  If you are a woman and breast cancer runs in your family, strongly consider abstinence.  Be cautious if there are alcoholics in your family; you may have inherited the pre-disposition.  If you take any medications or have chronic medical conditions, check with your personal physician first.

For those drinking above light to moderate levels, alcohol is clearly perilous.  Higher dosages can cause hypertension, liver disease, heart failure, certain cancers, and other medical problems.  And psychosocial problems.  And legal problems.  And death.  Heavy drinkers have higher rates of violent and accidental death.  Alcoholism is often fatal. 

You should not drink alcohol if you . . .

■  have a history of alcohol abuse or alcoholism
■  have liver or pancreas disease
■  are pregnant or trying to become pregnant
■  may have the need to operate dangerous equipment or machinery, such as an automobile, while under the influence of alcohol
■  have a demonstrated inability to limit yourself to acceptable intake levels
■  have personal prohibitions due to religious, ethical, or other reasons.

Steve Parker, M.D.

Author of The Advanced Mediterranean Diet

References: Lieber, Charles S.  Alcohol and health: A drink a day won’t keep the doctor away.  Cleveland Clinic Journal of Medicine, 70 (2003): 945-953.

1 Comment

Filed under Alcohol

Dental Problems and Systemic Chronic Disease: A Carbohydrate Connection?

Perfect health on a carnivorous, low-carb diet

Perfect health on a carnivorous, low-carb diet

Dentists are considering a return to an old theory that dietary carbohydrates first cause dental diseases, then certain systemic chronic diseases, according to a review in the June 1, 2009, Journal of Dental Research

We’ve known for years that some dental and systemic diseases are associated with each other, both for individuals and populations.  For example, gingivitis and periodontal disease are associated with type 2 diabetes and coronary heart disease.  The exact nature of that association is not clear.  In the 1990s it seemed that infections – chlamydia, for example – might be the unifying link, but this has not been supported by subsequent research.     

The article is written by Dr. Philippe P. Hujoel, who has been active in dental research for decades and is affiliated with the University of Washington (Seattle).  He is no bomb-throwing, crazed, radical. 

The “old theory” to which I referred is the Cleave-Yudkin idea from the 1960s and ’70s that excessive intake of fermentable carbohydrates, in the absence of good dental care, leads both to certain dental diseases – caries (cavities), periodontal disease, certain oral cancers, and leukoplakia – and to some common systemic chronic non-communicable diseases such as coronary heart disease, type 2 diabetes, some cancers, and dementia.  In other words, dietary carbohydrates cause both dental and systemic diseases – not all cases of those diseases, of course, but some.   

Dr. Hujoel does not define “fermentable” carbohydrates in the article.  My American Heritage Dictionary defines fermentation as:

  1. the anaerobic conversion of sugar to carbon dioxide and alcohol by yeast
  2. any of a group of chemical reactions induced by living or nonliving ferments that split complex organic compunds into relatively simple substances

As reported in David Mendosa’s blog at MyDiabetesCentral.com, Dr. Hujoel said, “Non-fermentable carbohydrates are fibers.”  Dr. Hujoel also shared some personal tidbits there. 

In the context of excessive carbohydrate intake, the article frequently mentions sugar, refined carbs, and high-glycemic-index carbs.  Dental effects of excessive carb intake can appear within weeks or months, whereas the sysemtic effects may take decades. 

Hujoel compares and contrasts Ancel Keys’ Diet-Heart/Lipid Hypothesis with the Cleave-Yudkin Carbohydrate Theory.  In Dr. Hujoel’s view, the latest research data favor the Carbohydrate Theory as an explanation of many cases of the aforementioned dental and systemic chronic diseases.  If correct, the theory has important implications for prevention of dental and systemic diseases: namely, dietary carbohydrate restriction.

Adherents of the paleo diet and low-carb diets will love this article; it supports their choices.

I agree with Dr. Hujoel that we need a long-term prospective trial of serious low-carb eating versus the standard American high-carb diet.  Take 20,000 people, randomize them to one of the two diets, follow their dental and systemic health over 15-30 years, then compare the two groups.  Problem is, I’m not sure it can be done.  It’s hard enough for most people to follow a low-carb diet for four months.  And I’m asking for 30 years?!   

Dr. Hujoel writes:

Possibly, when it comes to fermentable carbohydrates, teeth would then become to the medical and dental professionals what they have always been for paleoanthropologists: “extremely informative about age, sex, diet, health.”

Dr. Hujoel mentioned a review of six studies that showed a 30% reduction in gingivitis score by following a diet moderately reduced in carbs.  He mentions the aphorism: “no carbohydrates, no caries.”  Anyone prone to dental caries or ongoing periodontal disease should do further research to see if switching to low-carb eating might improve the situation. 

Don’t be surprised if your dentist isn’t very familiar with the concept.  Has he ever mentioned it to you?

Steve Parker, M.D.,

Author of The Advanced Mediterranean Diet

Reference:  Hujoel, P.  Dietary carbohydrates and dental-systemic diseasesJournal of Dental Research, 88 (2009): 490-502.

Mendosa, David.  Our dental alarm bell.  MyDiabetesCentral.com, July 12, 2009.

2 Comments

Filed under Carbohydrate, Causes of Diabetes, coronary heart disease, Glycemic Index and Load

Potential Beneficial Effects of Alcohol

FOD023For centuries, the healthier populations in the Mediterranean region have enjoyed wine in light to moderate amounts, usually with meals.  Observational studies there and in other parts of the world have associated reasonable alcohol consumption with prolonged lifespan, reduced coronary artery disease, diminished Alzheimer’s and other dementias, and possibly fewer strokes. 

Alcohol tends to increase HDL cholesterol, have an antiplatelet effect, and may reduce C-reactive protein, a marker of arterial inflammation. These effects would tend to reduce cardiovascular disease.  Wine taken with meals provides antioxidant phytochemicals (polyphenols, procyanidins) which may protect against atherosclerosis and some cancers.

What’s a “reasonable” amount of alcohol?  An old medical school joke is that a “heavy drinker” is anyone who drinks more than the doctor does.  Light to moderate alcohol consumption is generally considered to be one or fewer drinks per day for a woman, two or fewer drinks per day for a man.  One drink is 5 ounces of wine, 12 ounces of beer, or 1.5 ounces of 80 proof distilled spirits (e.g., vodka, whiskey, gin). 

The optimal health-promoting type of alcohol is unclear.  I tend to favor wine, a time-honored component of the Mediterranean diet.  Red wine in particular is a rich source of resveratrol, which is thought to be a major contributor to the cardioprotective benefits associated with light to moderate alcohol consumption.  Grape juice and grape extracts may be just as good—it’s too soon to tell.

Don’t miss my next blogging topic – “Potential Adverse Effects of Alcohol.”

Steve Parker, M.D.

Author of The Advanced Mediterranean Diet: Lose Weight, Feel Better, Live Longer  

References:

Standridge, John B., et al.  Alcohol consumption: An overview of benefits and risks.  Southern Medical Journal, 97 (2004): 664-672.

Luchsinger, Jose A., et al.  Alcohol intake and risk of dementia.  Journal of the American Geriatrics Society, 52 (2004): 540-546.

1 Comment

Filed under Alcohol

Medical Cost of Obesity Soars

Healthcare dollars

Healthcare dollars

A report released last week found that obese individuals in the U.S. spend an extra $1,429 yearly on healthcare compared to normal-weight people.  Furthermore, total U.S. cost of treating obesity-related conditions was $147 billion in 2008.

Unsure if you’re overweight or obese?  Find out with one of the body mass index calculators available on the Internet.

Are you obese and fed up with the extra expense?  Are you already suffering from overweight-related medical conditions?  If so, read my document on how to prepare for weight loss, then get started soon. 

Well-begun is half done.

Steve Parker, M.D.

Author of The Advanced Mediterranean Diet

Reference:  Finkelstein, E.A., et al.  Annual medical spending attributable to obesity: Payer and service-specific estimatesHealth Affairs, 28 (2009): w822-w831.

1 Comment

Filed under Overweight and Obesity

U.S. Food and Drug Administration Approves Saxagliptin (Onglyza) for Type 2 Diabetes

CB107673Yesterday, July 31, 2009, the FDA approved use of saxagliptin, a DPP4 inhibitor, in adults with type 2 diabetes as an adjunct to diet and exercise.  Bristol-Myers Squibb and AstraZeneca will sell the drug under the brand name Onglyza.

The drug’s only competitor in the U.S. market is Merck’s Januvia, which sold over $400 million in the first quarter of this year.

“How does saxagliptin work?”

Incretin hormones influence secretion of insulin and glucagon by the pancreas.  The dipeptidyl peptidase-4 (DPP4) enzyme inactivates these incretin hormones.  Saxagliptin inhibits the DPP4 enzyme, resulting in increased insulin production and decreased production of glucagon. 

“But it causes bad side effects, right?”

No, not that we know of yet.  Overall, incidence of side effects is similar to placebo side effects.  The drug may slightly increase headache, runny nose, and sore throat.  Risk of hypoglycemia is increased minimally, if at all. 

“Can I use Onglyza with my other diabetes drugs?”

It’s FDA-approved for use by itself or in combination with metformin, sulfonylureas, and thiazolidinediones. 

“What’s the dose?”

2.5 or 5 mg by mouth daily, without regard to meals. 

“Is this a tremendous breakthrough in treatment of type 2 diabetes?”

Probably not.  But it’s good to have another treatment option.  And competition among the drug manufacturers tends to bring down prices.   

Steve Parker, M.D.

References: 

Bristol-Myers Squibb.   Press Release from Bristol-Myers Squibb, July 31, 2009.

Goldstein, Jacob.  Saxagliptin approval: Finally, competition for Merck’s Januvia.  WSJ.com Health Blog, July 31, 2009.

Comments Off on U.S. Food and Drug Administration Approves Saxagliptin (Onglyza) for Type 2 Diabetes

Filed under Drugs for Diabetes

Glycemic Load Linked to Breast Cancer Risk

Who knew?

Who knew?

Swedish researchers report that  a high dietary glycemic load is tied to a woman’s risk of developing breast cancer.  This adds to a growing body of evidence that high glycemic index and load may be harmful.  Prior studies relate them to higher rates of diabetes and heart disease. 

Click here for my review of glycemic index and load.  NutritionData.com also has a good review of glycemic index.

Steve Parker, M.D.

References:

Reuters Health.  “Glycemic load” of diet tied to breast cancer risk.  MedlinePlus, July 10, 2009.

Parker, Steve.  Glycemic index and chronic disease risk (mostly in women).  Advanced Mediterranean Diet Blog, April 19, 2009.

Comments Off on Glycemic Load Linked to Breast Cancer Risk

Filed under Glycemic Index and Load